CL
NYMX

Croft-Leominster’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Croft-Leominster’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-20,000
Closed -$87K – 202
2014
Q3 		$87K Hold
20,000
– – 0.02% 194
2014
Q2 		$99K Hold
20,000
– – 0.02% 189
2014
Q1 		$109K Hold
20,000
– – 0.02% 188
2013
Q4 		$121K Buy
+20,000
New +$136K 0.02% 196

Other funds holding NYMX

AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
WP
WMS Partners Towson, Maryland $1.78B AUM 11.82% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
MCM
Marathon Capital Management Hunt Valley, Maryland $494M AUM 42.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BAS
Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return
GG
Gofen & Glossberg Chicago, Illinois $3.89B AUM 11.97% 1-Year Est. Return

Croft-Leominster's NYMX Position: Q4 2014 in Review

Croft-Leominster sold out of Nymox Pharmaceutical Corp (NYMX) in Q4 2014, closing a stake of 20,000 shares — an estimated $87K sold.

Croft-Leominster first reported a position in NYMX in Q4 2013 and held it in 4 quarters. The position peaked at $121K in Q4 2013. 25 funds tracked by Wall St. Rank hold NYMX as of Q4 2014.

  • Croft-Leominster reported no remaining Nymox Pharmaceutical Corp position as of Q4 2014 after selling out during the quarter.
  • Croft-Leominster sold 20,000 Nymox Pharmaceutical Corp shares in Q4 2014, an estimated $87K.
  • Croft-Leominster first reported a position in Nymox Pharmaceutical Corp in Q4 2013 and held it in 4 quarters.
  • Croft-Leominster's Nymox Pharmaceutical Corp position peaked at $121K in Q4 2013.
  • 25 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q4 2014.

Based on Croft-Leominster's 13F filing for Q4 2014, filed 17 Feb 2015.